Pull to refresh
Logo
Linton Lifesciences buys EnvisionTEC's 3D-Bioplotter business

Linton Lifesciences buys EnvisionTEC's 3D-Bioplotter business

Money Moves

A bioprinting platform first sold in 2000 moves to a Boston implant startup that plans a successor model

Overview

Updated 33 minutes ago

The 3D-Bioplotter has been on sale since 2000, when it came out of the University of Freiburg as the first extrusion-based biofabrication machine. On November 22, Linton Lifesciences said it had bought the platform, its technology and its operations from EnvisionTEC GmbH. The price was not disclosed.

Linton gets a research tool with a long customer list, more than 2,490 papers citing it, and a manufacturing record: an FDA 510(k)-cleared 3D-printed bone regeneration product was made on it in 2022 by a customer, not by Linton. Linton says it will keep supporting existing users while it builds the next version, and will run the machine both as a product it sells and as equipment for its own graft and tissue-model programs.

Why it matters

A 26-year-old research platform with 2,490 cited papers now sits inside a small implant startup that must decide whether to build its successor.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

2000
Year the 3D-Bioplotter launched
Developed at the University of Freiburg and sold commercially from 2000.
2,490+
Research papers citing the 3D-Bioplotter
Count published on Linton's platform page, which says it rebuilt the citation database.
$300M
What Desktop Metal paid for EnvisionTEC in 2021
Cash and stock for the whole company, of which the Bioplotter was one product line.
8
Modular printheads on the platform
Linton lists printheads covering 2 °C to 500 °C.
2
Sites after the deal
Boston headquarters plus EnvisionTEC's historic Gladbeck, Germany location.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

2000 November 2026

9 events Latest: Today
Tap a bar to jump to that date
  1. Linton acquires the 3D-Bioplotter platform

    Today Acquisition

    Linton takes over the platform, technology and operations, adds a Gladbeck site, and pledges a next-generation model.

  2. Linton introduces perfusable tissue models

    Product

    The company unveils tubular tissue models intended to replace some static laboratory testing.

  3. Desktop Metal files Chapter 11; EnvisionTEC GmbH sold

    Bankruptcy

    EnvisionTEC GmbH goes to an affiliate of Anzu Partners as part of the foreign subsidiary sales.

  4. Linton Lifesciences launches in Boston

    Company

    The startup starts with a biofabricated vascular graft for hemodialysis access as its first target.

  5. PrintRoll rotating platform added for cylindrical scaffolds

    Product

    The accessory lets users print vessels, airways and nerve conduits directly as cylinders.

  6. First 510(k)-cleared bone graft made on the platform

    Regulatory

    A customer's 3D-printed regenerative bone product clears FDA review after being manufactured on the Bioplotter.

  7. Desktop Metal buys EnvisionTEC for $300 million

    Acquisition

    EnvisionTEC becomes a wholly owned Desktop Metal subsidiary, keeping founder Al Siblani as chief executive.

  8. Manufacturer Series ships with medical traceability camera

    Product

    Fourth-generation system targets academic and commercial users, adding a camera for traceability.

  9. First 3D-Bioplotter prototype published

    Technology

    Developed at the University of Freiburg, it becomes the first extrusion-based biofabrication system.

Scenarios

1

Linton announces a next-generation 3D-Bioplotter

Possible Resolves by End of 2027

Discussed by: Linton's own acquisition statement, which says it is investing in the next generation of the platform

Linton has committed publicly to a successor machine and keeps the existing product lead and German site. A launch would likely combine the current multi-printhead architecture with hardware aimed at regulated manufacturing, matching how Linton describes its own production needs. The trigger to watch is a product page or release naming a new model.

2

Linton's vascular graft reaches a first human implant

Uncertain Resolves by End of 2028

Discussed by: Linton's launch materials, which name a biofabricated graft for hemodialysis access as its first product target

The Bioplotter acquisition matters most if it becomes production equipment rather than only a research instrument. That depends on the graft program moving from bench work into a clinical study. Watch for a regulatory filing, a trial registration, or a named clinical partner.

3

The Bioplotter changes hands a third time

Unlikely Resolves by Q2 2028

Discussed by: No public forecasts yet; included because the platform has now moved between three owners in five years

EnvisionTEC held the platform for about two decades. Desktop Metal held it for four years, and the German entity passed to Anzu Partners before the product line went to Linton. If hardware sales do not fund the successor development, another transfer or a licensing arrangement is plausible.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

February 2021

Desktop Metal acquires EnvisionTEC (2021)

Desktop Metal paid $300 million in cash and stock for EnvisionTEC, a German maker of photopolymer 3D printers that also owned the 3D-Bioplotter. Desktop Metal described the target as a pioneer in biofabrication for biocompatible medical parts, including bone and cartilage regeneration.

Then

EnvisionTEC ran as a wholly owned subsidiary under founder Al Siblani, and the Bioplotter gained a place inside a publicly traded American manufacturer.

Now

Desktop Metal filed for Chapter 11 in July 2025, and EnvisionTEC GmbH was sold to an affiliate of Anzu Partners, separating the bioprinting line from its parent.

Why this matters now

The Bioplotter has now passed through a large industrial owner and a bankruptcy sale. Linton's purchase is the third hand-off, and the first time the buyer's core business is implants rather than printers.

2021

3D Systems acquires Allevi (2021)

Allevi, a bioprinter maker co-founded by Ricky Solorzano, was acquired by 3D Systems. The deal folded a small, research-focused hardware company into a larger additive manufacturing group.

Then

Solorzano left the hardware business he had built, and Allevi's machines became part of a broader 3D Systems portfolio.

Now

Five years later Solorzano is running a bioprinting hardware line again, but as a side business to implant development rather than the main product.

Why this matters now

It explains why this deal is a return rather than a debut for Linton's chief executive, and why the incentives differ: the hardware now exists to serve an implant pipeline.

Sources

(7)